AB Sciex

Advantages like better accuracy and easier assay development could help HRAM systems carve out space in a market currently dominated by triple quadrupoles.

The platform is a streamlined device targeting hospitals and other labs interested clinical mass spec but lacking the expertise required by traditional systems.

Anticipating a potential cut into its portfolio from competitors' mass specs, Roche said last week at AACC that it will develop its own mass spec-based analyzer in response.

The company is targeting hospital labs interested in a more streamlined mass spec solution as the clinical mass spec market begins to heat up.

The Triple Quad 4500MD LC-MS/MS system, which consists of the LC-MS/MS platform along with Sciex's Analyst MD, Cliquid MD, and MultiQuant MD software, can be used for in vitro diagnostics.

Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.

Called the Vitamin D 200M Assay, the kit runs on Sciex's Topaz LC-MS System and is the only FDA-cleared LC-MS-based Vitamin D assay kit currently on the market.

A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.

Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent

The company has made significant progress implementing large-scale discovery workflows though challenges remain in terms of translation to the clinic.